Instead of stimulating MET by activating a specific transcription factor or signaling pathway, in many in vitro and in vivo cancer studies, MET is activated by silencing an EMT-inducing signal such as TGF-ß or by downregulating an EMT-TF [27,28,29,30]. The gene discussed is TF; the disease is cancer.